key: cord-0695982-jr75aphr authors: Sharma, Aseem; Mhatre, Madhulika; Goldust, Mohamad; Jindal, Veenu; Singla, Palvi title: The COVID‐19 chemoprophylactic conundrum – Are we limiting available resources? date: 2020-05-17 journal: Dermatol Ther DOI: 10.1111/dth.13607 sha: 53d4c8caf425722571f401670b35309295be0bb9 doc_id: 695982 cord_uid: jr75aphr nan (Yao, 2020) Hydroxychloroquine has demonstrated anti-SARS-CoV-2 action in vitro as it inhibits angiotensin-converting-enzyme-2 (ACE-2) receptor and viral polymerases. (Colson, 2020; Yao, 2020; Fox, 2020) The recommended dosage for HCQ chemoprophylaxis is 400mg BD on day 1 followed by 200mg weekly for next seven weeks. Emerging prophylaxis strategies against COVID-19 Monaldi Archives for Chest Disease Chloroquine and hydroxychloroquine as available weapons to fight COVID-19